---
document_datetime: 2025-11-23 07:07:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ecokinase.html
document_name: ecokinase.html
version: success
processing_time: 0.0420265
conversion_datetime: 2025-12-28 08:25:50.726053
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ecokinase

[RSS](/en/individual-human-medicine.xml/66853)

##### Withdrawn

This medicine's authorisation has been withdrawn

reteplase

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 29 August 1996, the European Commission issued a Marketing Authorisation valid throughout the European Union for the medicinal product Ecokinase, which contains reteplase. The pharmaceutical company responsible for this medicinal product was Galenus Mannheim.

On 28 January 1999, the Marketing Authorisation holder notified the European Commission about their decision to withdraw the Marketing Authorisation for Ecokinase.

On 30 July 1999, the European Commission adopted the decision withdrawing the Marketing Authorisation for this medicinal product for human use \"ECOKINASE - Reteplase\" EU/1/96/017/001. Pursuant to this decision the European Public Assessment Report for Reteplase has been removed from the EMA website.

For information, it should be noted that there is still a Marketing Authorisation valid throughout the European Union for another product Rapilysin, which contains reteplase. The pharmaceutical company responsible for this medicinal product is Roche Registration Ltd., UK.

## Product information

30/07/1999

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine Ecokinase Active substance reteplase International non-proprietary name (INN) or common name reteplase Therapeutic area (MeSH) Myocardial Infarction Anatomical therapeutic chemical (ATC) code B01AD07

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

Thrombolytic therapy of acute myocardial infarction

## Authorisation details

EMA product number EMEA/H/C/000106 Marketing authorisation holder

Roche Registration Ltd.

6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom

Marketing authorisation issued 29/08/1996 Withdrawal of marketing authorisation 30/07/1999

**This page was last updated on** 12/12/2000

## Share this page

[Back to top](#main-content)